MANY MINDEDMelanoma vaccine trial shows longer cancer-free periods for high-risk patients
Moderna and Merck’s mRNA-based therapeutic vaccine candidate intismeran, designed to target patient-specific melanoma neoantigens, demonstrated longer cancer-free periods in a clinical trial for high-risk patients. Patients receiving intismeran combined with Keytruda (a PD-1 inhibitor already approved for cancer) showed improved outcomes versus Keytruda alone. The trial results were published online August 19, 2026 — a date likely typographical in the source material. This represents a potential 50% reduction in recurrence risk based on prior trials, though full data remains pending. Melanoma causes over 100,000 new US diagnoses and 8,500 deaths annually, making this advance significant for high-risk cases. Intismeran is not yet FDA-approved, and the results reflect interim data.
This approach could reduce long-term healthcare costs and mortality for melanoma patients by training the immune system to recognize cancer cells. However, the vaccine remains experimental and not yet available for clinical use. What matters next is whether full trial data confirms the interim findings and whether regulatory approval follows. The current status is pre-approval: the vaccine is in development but not yet accessible to patients.
Source: Science News